EVIDENCE-BASED MEDICAL PRACTICE

Did We Learn Evidence-Based Medicine in Medical School? Some Common Medical Mythology

Douglas S. Paauw, MD

Despite advances in medicine occurring on a daily basis, physicians are slow to change their practices. Many different interventions have been studied, including continuing medical education (CME) courses, computerized reminder systems, printed monographs, and CME home reading materials.1,2 The most common forms of updating information—CME courses and home reading materials—have little impact on changing professional practices.1,2 Physicians rely on a core knowledge base acquired in medical school and through subsequent experiential learning. Much of what is practiced and taught in medicine is based on plausible theory, but in some cases there is no direct evidence to support it. Some practices are grandfathered in with no questioning as to the validity of what is taught or practiced.

The purpose of this article is to look at several different medical myths and explore what is available in the literature to counter or offer alternatives to long-held beliefs.

Methods
MEDLINE was searched for relevant English language articles published between January 1976 and July 1998 using the following terms or combination of terms: “myths,” “oral vitamin Bl2 replacement,” “eye patch and corneal abrasion,” “adverse effects of beta-blockers,” “beta-blockers and hypoglycemia,” “beta-blockers and depression,” “insulin sliding scale,” and “narcotics and abdominal pain.” Relevant articles and bibliographies were reviewed to find articles published before 1976 as well as to search for articles not included in the original search.

Some Common Medical Myths
Case 1
An 84-year-old woman is seen in clinic for weakness and fatigue. When she is examined, her mental status is normal, and there is evidence of bilateral lower extremity neuropathy. Her hematocrit is 23 percent, hemoglobin 7.3 g/dL, and mean corpuscular volume 117/μm3. Her serum cobalamin level is 80 pg/mL (normal > 200 pg/mL), and her urinary methylmalonic acid level is high. A Schilling test is abnormal and corrects with addition of intrinsic factor, indicating pernicious anemia. She is given loading doses of hydroxocobalamin intramuscularly and told she will need a monthly injection of hydroxocobalamin to manage her disease.

Myth 1: Replacement for vitamin B12 deficiency caused by pernicious anemia must not be done orally.
The classic teaching in medical school is that vitamin B12 deficiency in patients with pernicious anemia is due to poor B12 absorption because of lack of intrinsic factor and that replacement must be given intramuscularly. This belief was expressed in the following statement by the United States Pharmacopeia Anti-Anemia Preparations Advisory Board: “In the management of a disease for which parenteral therapy with Vitamin B12 is a completely adequate and wholly reliable form of therapy, it is unwise to employ a type of treatment which is, at best, unpredictably effective.”3

Studies in the 1950s showed that vitamin B12 could be absorbed orally by patients with pernicious anemia and that two mechanisms of absorption of B12 exist, one that involves intrinsic factor and one that does not.4 Several studies showed that oral replacement with vitamin B12 could lead to resolution of the anemia.5-8 With oral vitamin

Submitted, revised, 10 Oct 1998.
From the Division of General Internal Medicine, University of Washington School of Medicine, Seattle. Address reprint requests to Douglas S. Paauw, MD, Division of General Internal Medicine, School of Medicine, University of Washington, 1959 NE Pacific St, Box 356420, Seattle, WA 98195-6420.
B₁₂ doses of less than 300 µg/d, daily serum levels were usually not in the normal range. Normal serum levels were readily achieved, however, when patients received 300 to 1000 µg of vitamin B₁₂ daily. In one study all 64 patients receiving oral daily dosages of 500 or 1000 µg of vitamin B₁₂ for pernicious anemia had normal serum B₁₂ levels, normalized hemoglobin levels, and no neurologic complications at follow-up through 5 years. Daily oral replacement of vitamin B₁₂ with 1000 µg keeps body stores of B₁₂ as adequately filled as monthly intramuscular delivery.

The costs of oral and parenteral vitamin B₁₂ replacement are comparable. The cost of 100 tablets of 1000 µg of vitamin B₁₂ is less than $10. Thirty injection doses of B₁₂ are also less than $10, but charges for administration either by clinic personnel or a visiting nurse dramatically increase the monthly cost. Even if patients were able to give themselves the vitamin B₁₂ injection, there would be additional costs for the monthly syringes, needles, and alcohol wipes.

Why is oral vitamin B₁₂ not widely used for replacement? Most physicians do not believe that vitamin B₁₂ can be replaced orally. In a survey of internists, 94 percent were not aware of an available, effective oral therapy for B₁₂ replacement. In the same survey, 88 percent of the internists stated that an oral replacement form of vitamin B₁₂ would be useful in their practice.

This myth combines several features found in medical myths. It makes some sense from a pathophysiologic standpoint—vitamin B₁₂ requires intrinsic factor; if the patient does not have intrinsic factor, how would the patient absorb B₁₂? The studies that refuted the myth were published during a time (1960s) when oral vitamin B₁₂ was not available in the United States, so oral replacement did not become standard practice. Finally, the earliest results of studies of oral vitamin B₁₂ replacement using low doses of B₁₂ were failures.

**Case 2**

A 26-year-old man is evaluated for right eye pain. He was poked in the eye while playing basketball. He describes considerable right eye discomfort but no visual changes. On examination with fluorescein, he has evidence of a corneal abrasion. He is instructed to wear an eye patch over the right eye for the next 48 hours.

**Myth 2: Patching the eye improves comfort and healing in patients with corneal abrasions.**

The traditional treatment for corneal abrasions has been to apply a firm eye patch for several days. This standard approach is not based on any evidence of benefit of healing or decreased pain. A study in 1960 evaluated differences in healing of corneal abrasions comparing patients wearing an eye pad with patients not wearing an eye pad. No differences were seen in healing, and the author concluded that simple corneal abrasions should be treated without an eye pad. Several more recent studies have supported the recommendation to avoid patching the eye of patients with simple corneal abrasions. The largest of these studies involved 201 patients with corneal abrasions. The patients who did not receive an eye patch had less pain and quicker healing of the corneal abrasions.

No human studies were done to support the initial use of eye patches for the treatment of corneal abrasions. The first study questioning this practice, published in 1960, showed no benefit of eye patching. Despite evidence to the contrary, eye patching continued to be the standard of care for treatment of corneal abrasions and still is the common treatment offered for patients with corneal abrasion.

**Case 3**

A 48-year-old man with type 1 diabetes comes in for primary care. He has a history of gout, hypertension, and coronary artery disease, and he suffered a myocardial infarction 9 months ago. His hypertension was treated with lisinopril, but the medication was stopped 2 months later because he developed angioedema. His blood pressure is 160/95 mmHg, and his pulse is 80 beats per minute; he has nonproliferative retinopathy in both eyes and bilateral neuropathy in both lower extremities. Diltiazem is prescribed for his hypertension.

**Myth 3: Patients with diabetes are at increased risk for hypoglycemic unawareness if they are taking β-blocker.**

This patient with diabetes meets treatment guidelines for pharmacologic therapy for his hypertension. A β-blocker would offer both antihypertensive and cardioselective treatment and a cardioprotective benefit after a myocardial infarction. Concern about the side
effects of β-blockers appears to limit their use despite clear evidence of benefit. In the Cardiac Arrhythmia Suppression Trial (CAST) study, 50 percent of the patients received a calcium channel blocker after a myocardial infarction and approximately 30 percent received a β-blocker. The cardiovascular benefit of β-blockers in patients with diabetes who have had a myocardial infarction is striking. The mortality benefit in patients with diabetes who are given a β-blocker after a myocardial infarction is 48 percent, with a 78 percent decrease in reinfarction.

For patients with insulin-treated diabetes there is concern about β-blockers reducing or eliminating the warning symptoms of hypoglycemia. This concern was addressed by Barnett et al in a prospective study of 150 patients who had insulin-treated diabetes. Fifty diabetic patients on insulin taking β-blockers were compared with 100 diabetic patients on insulin not taking β-blockers. The patients kept a diary, recording all episodes of hypoglycemia and all warning symptoms. The incidence of loss of consciousness from hypoglycemia was the same in both groups and was not related to the dose of β-blocker used. All symptoms of hypoglycemia were similar in both groups with the exception of diaphoresis, which was more common in the β-blocker group.

In another study patients with diabetes on β-blockers were given insulin infusions to reduce blood glucose levels, and symptoms were recorded. The patients on β-blockers did not have hypoglycemic unawareness. They did have adrenergic symptoms at lower blood glucose levels than did the diabetic control group not on β-blockers, but their overall symptom scores were greater because of an increased perception of diaphoresis in the patients taking β-blockers. In a recent retrospective cohort study, more than 13,000 patients with diabetes treated with either oral hypoglycemics or insulin were studied to find out whether antihypertensive agents predisposed them to serious hypoglycemic events. No class of antihypertensive medication (including β-blockers) was found to predispose these patients to serious hypoglycemic events.

Case 4
A 67-year-old man is admitted with severe chest pain, and an acute inferior myocardial infarction is diagnosed. He undergoes coronary artery catheterization and has atherosclerotic disease in his left anterior descending and right coronary arteries. He is given atenolol, simvastatin, aspirin, and nitroglycerin (as needed). Three months after the infarct, he returns to the clinic with symptoms of insomnia, difficulty concentrating, feelings of worthlessness, and fatigue. He has no history of depression. His atenolol is tapered off, and sertraline is prescribed.

Myth 4: β-Blockers are an important cause of depression. Early reports of possible β-blocker-induced depression surfaced soon after the β-blocker propranolol became available in the 1960s. A frequently cited reference is a letter published in the British Medical Journal in which Waal reported that 20 of 89 patients on propranolol volunteered or exhibited depressive symptoms. Forty percent of these cases were classified as grade 1 depression—symptoms of irritability, insomnia, nightmares, and fatigue. No control group of patients was evaluated to ascertain the prevalence of these symptoms in patients treated with other antihypertensive medications or in nonhypertensive patients. Pollack et al described a series of 3 patients who developed symptoms of depression after starting propranolol and concluded that depression coming after the administration of propranolol was a real phenomenon.

A number of studies have concluded that there appears to be no increased prevalence of depression in patients on β-blockers. Schleifer et al evaluated for evidence of depression 190 patients who had sustained a myocardial infarction. The patients were interviewed 8 to 10 days after the infarct and again at 3 months. No antanginal or antihypertensive medication including β-blockers was associated with an increase in depression. Using a psychiatric interview and psychologic assessments, Carney et al evaluated 75 patients undergoing elective cardiac catheterization. One half of the patients in the study were receiving β-blockers. Thirty-three percent of the patients who were not receiving β-blockers met Diagnostic and Statistical Manual or Mental Disorders, ed 3 (DSM-III) criteria for depression, and 21 percent of the patients taking β-blockers met criteria for depression.

In a study of depression in new users of antihypertensive medications in the Harvard Community Health Plan medication registry, the rates of depression were no higher in those taking β-
The acute abdomen might mask the signs and make it difficult to make a diagnosis. Studies have shown that 6.4 percent of β-blocker users received a prescription for an antidepressant within 30 days compared with 2.8 percent of the reference group. A similar study design by Hallas showed no increase in antidepressant prescribing after patients received a β-blocker.

A great deal of concern about the possibility of β-blockers causing depression was generated by early case reports and subsequent case series. None of these reports evaluated the frequency of depression in a control group. Confounding the issue is the side effect of fatigue, which is frequently reported in patients on β-blockers. Patients might have depression incorrectly diagnosed if fatigue is the only depressive symptom. Depression occurring after major medical illness such as an myocardial infarction is common. As several studies have shown, depression is common in patients with coronary artery disease regardless of what specific medications they are taking. Unfortunately, no large controlled prospective trials have addressed the issue of depression in patients taking β-blockers. The beneficial effects of β-blockers should not be overlooked in patients who have a history of depression, as the small possibility of a depressive effect caused by the β-blocker might well be outweighed by its beneficial effect.

**Case 5**
A 33-year-old man comes to the emergency department with acute abdominal pain. He had the sudden onset of pain in the middle of his abdomen about 2 hours earlier. The pain is worse with movement, particularly during the car ride to the hospital. He recently injured his leg snowboarding and has been taking a large amount of aspirin to relieve the pain. When examined, the patient has a rigid abdomen with tenderness on palpation. He asks for pain medication but is told he needs to be evaluated by the surgeon before medication can be considered.

**Myth 5:** Giving narcotics to a patient with a possible acute abdomen might mask the signs and make it difficult to make a diagnosis.
artery disease with a history of a myocardial infarction 2 years ago, and a history of hypertension. Her medications include isosorbide dinitrate 20 mg orally three times a day, enalapril 10 mg orally every morning, enteric-coated aspirin 325 mg daily, and glyburide 10 mg orally twice a day. Laboratory values at admission were as follows: sodium 130 mEq/L, potassium 3.8 mEq/L, chloride 98 mEq/L, bicarbonate 24 mEq/L, and glucose 440 mg/dL. She is given intravenous ampicillin-sulbactam for her foot ulcer and begins a sliding scale insulin regimen for management of her diabetes.

Myth 6: Sliding scale insulin therapy is effective and appropriate therapy for managing diabetes in hospitalized patients.

Most training in the management of diabetes mellitus in the United States takes place during medical school and residency in the inpatient setting. Sliding scale insulin injections are a commonly used management strategy for hospitalized patients. In a study of medical inpatients, physicians prescribed a sliding scale regimen for 61 percent of 218 patients with a history of diabetes who were admitted to the hospital for reasons other than metabolic control. It is not clear how this practice began. There are no studies showing benefit of a sliding scale approach to diabetes management. It became firmly entrenched as a popular method of so-called “cookbook” medicine, usually learned during residency training.

Initial sliding scale insulin regimens were based on urine glucose levels. Current sliding scale insulin regimens are based on regularly obtained fingerstick glucose values, usually obtained at 4- to 6-hour intervals. Problems with this approach include giving insulin retrospectively for high blood glucose levels and not giving any insulin when the patient achieves euglycemia regardless of caloric intake. Insulin is not given in anticipation of rising blood glucose levels with meals. Patients frequently receive blood glucose monitoring at bedtime or even during the night when there is no food intake. Treating elevated evening blood glucose levels with regular insulin increases the risk of hypoglycemic episodes while the patient is asleep and less likely to be able to call for assistance.

Several studies have evaluated the efficacy of sliding scale insulin therapy. Gearheart et al evaluated outcomes of patients admitted for treatment of diabetic ketoacidosis. Insulin therapy was effective and probably endured for this reason despite no evidence in the literature to support it. Sliding scale insulin had a longer duration of ketosis and worse glucose control than those who received long-acting insulin. In a recent study Queale et al reviewed the diabetes management of 171 hospitalized patients, of whom 130 were given sliding scale insulin regimens. When used alone (without long-acting insulin), the sliding scale insulin regimens were associated with a threefold higher risk of hyperglycemic episodes compared with no pharmacologic regimen. This study also touches on another problem with sliding scale insulin regimens—they are rarely modified. Patients at higher risk in this study for hypoglycemia were men with low body weight and those patients with low serum albumin levels. The sliding scale regimen written on admission was rarely ever modified during the hospitalization.

Alternatives to sliding scale insulin for management of the hospitalized patient with diabetes include intravenous insulin drips in the patient who is not able to eat or long-acting daily insulin with premeal adjustments in regular insulin dosing based on an insulin algorithm. Algorithms differ from sliding scales in that they are connected to meal times and take into account calorie load and activity level. A key factor in safely giving insulin in the hospital setting is checking blood glucose levels around meal time and making any adjustment to short-acting insulin doses based on both premeal glucose level and anticipated caloric intake.

Why did sliding scale insulin use become such a widespread practice? It reduces diabetes management into a simple, easy-to-remember formula and probably endured for this reason despite no evidence in the literature to support it. Sliding
scale insulin allows preordered insulin dosages to be given automatically based on serum glucose monitoring without interrupting the physician for intermittent insulin orders. The few studies that have been published suggest it is an inferior management choice compared with longer acting insulin or intravenous insulin infusions.

Summary
Medical myths occur for many different reasons. A common thread is that they all make some pathophysiologic sense. A good example is the concern about using oral cobalamin when treating pernicious anemia. The difficulty in absorbing vitamin B₁₂ when intrinsic factor is not available does not make oral replacement impossible; the dose just needs to be higher. Pathophysiologic concerns have also been a key reason why physicians have avoided using β-blockers in patients with diabetes. They fear that β-blockers will block adrenergic symptoms, and patients will not know when they are hypoglycemic. In studies addressing this issue, there appears to be no real problem with increased severe episodes of hypoglycemia in patients on β-blockers or increased hypoglycemic unawareness. Several studies commented on the unanticipated symptom of increased sweating associated with hypoglycemia in diabetic patients who are taking β-blockers.

Another important concept behind some medical myths is the overreliance on case reports or authoritative text. The concern about depression associated with β-blocker use grew out of one widely referenced case report. Subsequent studies have not shown convincing evidence for a strong association with β-blocker use and depression. The strong position taken against narcotic use in Cope’s Early Diagnosis of the Acute Abdomen is probably the reason for the perpetuation of the myth of avoiding narcotics for pain relief in patients with undiagnosed acute abdominal conditions. The only two studies addressing this issue showed no problems with diagnosis caused by providing narcotic pain relief.

Newer therapies usually undergo closer scrutiny before being accepted, often including placebo-controlled trials to show the efficacy of a medication. Such might not be the case with newer technologies. It is harder to evaluate the benefit of a new technology in the face of non-comparable previous technologies. Catheterization of the right side of the heart (Swan-Ganz catheter) was a technology that became widely used before any outcome studies became available. Multiple reports in the last decade have shown increased mortality and increased utilization of resources in patients who received catheterization of the right side of the heart.

Most new drug therapies require randomized data to show efficacy before widespread use and acceptance occurs. Older therapies that have been widely accepted for a long time might not have had controlled trial data behind recommendations for their use, and once practice patterns become widespread, it is hard to change.

It is always good to ask the question, “Will this help my patient live better or longer?” when prescribing a therapy. These myths underscore the importance and utility of outcome-based research to help guide physicians in their practices.

References